UNDERSTANDING THE UTILITY VALUE OF PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Hadi, M. [1 ]
Swinburn, P. [1 ]
de Freitas, H. M. [1 ]
Ito, T. [2 ]
机构：
[1] Mapi Grp, London, England
[2] Janssen Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.242
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM175
引用
收藏
页码：A389 / A389
页数：1
相关论文
共 50 条
  • [31] Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer
    Rasmussen, Maja Lynge
    Liposits, Gabor
    Yogendram, Subethini
    Jensen, Anders Bonde
    Linnet, Soren
    Langkjer, Sven Tyge
    ACTA ONCOLOGICA, 2014, 53 (09) : 1275 - +
  • [32] Thalidomide-induced peropheral neuropathy in newly diagnosed and pre-treated multiple myeloma patients.
    Tosi, P
    Zamagni, E
    Cellini, C
    Cangini, D
    Tacchetti, P
    Perrone, G
    Tura, S
    Baccarani, M
    Cavo, M
    BLOOD, 2004, 104 (11) : 306B - 307B
  • [33] INDIRECT COMPARISON OF DARATUMUMAB MONOTHERAPY VERSUS REAL-WORLD HISTORICAL CONTROL DATA IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE HEAVILY PRE-TREATED AND HIGHLY REFRACTORY
    Diels, J.
    Lam, A.
    Ito, T.
    Ng, Y.
    Mehra, M.
    Khan, I
    VALUE IN HEALTH, 2016, 19 (03) : A140 - A140
  • [34] AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS
    Kumar, S. K.
    Durie, B. G.
    Diels, J.
    Bacon, T.
    Soltoft, F.
    Lam, A.
    HAEMATOLOGICA, 2017, 102 : 273 - 274
  • [35] The prognostic value of total cell free DNA measurement in patients with heavily pre-treated metastatic colorectal cancer treated with gemcitabine and capecitabine
    Spindler, K. Garm
    Pallisgaard, N. P.
    Andersen, R. F. A. Fredslund
    Ploeen, J.
    Jakobsen, A. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S566 - S566
  • [36] Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
    Chen, Pei-Hsin
    Yeh, Dah-Cherng
    Tung, Heng-Hsin
    Lin, Chin-Yao
    MEDICINE, 2021, 100 (47)
  • [37] Increased survival for heavily pre-treated metastatic breast cancer
    Siddall, Rhonda
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (07) : 370 - 370
  • [38] Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
    Bartsch, Rupert
    Wenzel, Catharina
    Gampenrieder, Simon P.
    Pluschnig, Ursula
    Altorjai, Gabriela
    Rudas, Margaretha
    Mader, Robert M.
    Dubsky, Peter
    Rottenfusser, Andrea
    Gnant, Michael
    Zielinski, Christoph C.
    Steger, Guenther G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 903 - 910
  • [39] Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
    Rupert Bartsch
    Catharina Wenzel
    Simon P. Gampenrieder
    Ursula Pluschnig
    Gabriela Altorjai
    Margaretha Rudas
    Robert M. Mader
    Peter Dubsky
    Andrea Rottenfusser
    Michael Gnant
    Christoph C. Zielinski
    Guenther G. Steger
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 903 - 910
  • [40] Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer
    Qvortrup, Camilla
    Jensen, Benny Vittrup
    Jorgensen, Trine Lembrecht
    Nielsen, Dorte
    Bjerregaard, Jon Kroll
    Pfeiffer, Per
    ACTA ONCOLOGICA, 2010, 49 (06) : 833 - 836
12345